Trial Profile
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms PemCab
- 18 Mar 2024 Planned End Date changed from 17 May 2026 to 31 May 2024.
- 27 Jan 2024 Results (Between December 26, 2018, and April 19, 2023) assessing the safety and efficacy of cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma, presented at the 2024 Genitourinary Cancers Symposium.
- 09 Oct 2023 Planned End Date changed from 1 Sep 2023 to 17 May 2026.